Canagliflozin (marketed under the brand name Invokana) is one of a newer class of diabetes drugs, the SGLT-2 Inhibitors, that have received much attention in the last few years.  Now a new study shows that patients taking canagliflozin have a significantly reduced risk of heart attacks and strokes when compared to placebo. Since most patients with diabetes die from heart-related health issues, the cardiac benefits of SGLT-2 Inhibitors are big news. Read more